After a round of antibiotics,
dysbiosis can remain—
that means the C. diff battle
isn’t over.
It's time for VOWST
following antibiotics to knock
out recurrence^5,6

*Clostridioides difficile (C. diff) infection.

rCDI, recurrent C. diff infection.

References: 1. VOWST [Prescribing Information]. Bridgewater, NJ: Aimmune Therapeutics, Inc. 02/2025. 2. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220-229. doi:10.1056/NEJMoa2106516 3. Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information: Guidance for Industry. Center for Biologics Evaluation and Research, US Food and Drug Administration. Updated August 16, 2018. Accessed June 2, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-clinical-trials-live-biotherapeutic-products-chemistry-manufacturing-and-control-information 4. Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022;328(20):2062-2064. doi:10.1001/jama.2022.16476 5. Jain N, Umar TP, Fahner A-F, Gibietis V. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications. Gut Microbes. 2023;15(1):2232137. doi:10.1080/19490976.2023.2232137 6. Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23(1):132. doi:10.1186/s12879-023-08096-0 7. Sims MD, Khanna S, Feuerstadt P, et al; ECOSPOR IV Investigators. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint Recurrence at 8 weeks* Secondary Endpoints Adverse events within 24 weeks Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin

Peers and patients discuss their struggles with rCDI and how they found VOWST

VOWST support programs help patients and providers along the way

VOWST oral dosing follows standard-of-care antibiotics and a laxative1,2

VOWST is proven efficacious and generally well tolerated1,7

rCDI can be serious, including risk of mortality6

Hear from Dr. Feuerstadt on his approach to treating rCDI with VOWST

Peers and patients discuss
their struggles with rCDI and
how they found VOWST

VOWST support programs
help patients
and providers along the way

VOWST oral dosing follows
standard-of-care antibiotics
and a laxative^1,2

VOWST is proven efficacious
and generally well tolerated^1,7

rCDI can be serious, including
risk of mortality⁶

Hear from Dr. Feuerstadt on
his approach to treating rCDI
with VOWST